Corcept Therapeutics (CORT) stock shot up over 100% yesterday as markets reacted to the company’s announcement of promising outcomes from its ...

Corcept Therapeutics Incorporated (NASDAQ:CORT) just the other day announced that it had achieved the primary endpoint of its pivotal phase 3 ROSELLA study. This late-stage study tested the ...

Shares of biopharma company Corcept Therapeutics (NASDAQ:CORT) jumped 94.9% in the afternoon session after the company announced that its Phase 3 trial (ROSELLA) met its goal of improving ...

Equities researchers at Zacks Research lifted their Q1 2026 earnings per share (EPS) estimates for shares of Corcept Therapeutics in a report released on Wednesday, April 2nd. Zacks Research analyst K ...

Corcept Therapeutics (CORT) announced the start of BELLA, a Phase 2 trial of relacorilant plus nab-paclitaxel and bevacizumab evaluating ...

The latest price target for Corcept Therapeutics (NASDAQ:CORT) was reported by Piper Sandler on April 3, 2025. The analyst firm set a price target for $131.00 expecting CORT to rise to within 12 ...

It has been about a month since the last earnings report for Corcept Therapeutics (CORT). Shares have lost about 5.3% in that time frame, underperforming the S&P 500. Will the recent negative ...